維信金科(02003.HK)擬發行8500萬美元2022年到期優先票據
格隆匯 11 月 27日丨維信金科(02003.HK)公佈,於2020年11月27日,公司與初始買家就同時發行新票據簽訂購買協議。待同時發行新票據的先決條件達成或獲豁免後,公司將發行本金總額為805.7萬美元的額外新票據。
額外新票據將與根據交換要約發行的本金金額為7694.3萬美元的新交換票據合併構成同一系列。合併後,新票據的未償付本金總額將為8500萬美元。額外新票據應於結算日(預期為2020年12月3日或前後)發行,並將於2022年12月3日到期。
發行額外新票據所得款項淨額主要用於一般營運資金用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.